[PDF][PDF] Preclinical studies of [Cu] ATSM as a PET radiopharmaceutical for fibrosarcoma imaging
ATSM) was prepared using in house-made diacetyl-bis (N4--methylthiosemicarbazone)(
ATSM) ligand and [61Cu] CuCl2 produced via the natZn (p, x) 61Cu (180 mA proton …
ATSM) ligand and [61Cu] CuCl2 produced via the natZn (p, x) 61Cu (180 mA proton …
Radiosynthesis and evaluation of [61Cu]-9,10-phenanthrenequinone thiosemicarbazone in fibrosarcoma-bearing animals for PET imaging
AR Jalilian, A Emami, M Akhlaghi… - rca-Radiochimica …, 2010 - degruyter.com
Abstract [61Cu]-9, 10-Phenanthrenequinone thiosemicarbazone (61Cu-PQTS), a
radiolabeled anticancer compound was prepared for malignant tissue imaging studies …
radiolabeled anticancer compound was prepared for malignant tissue imaging studies …
Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia
AL Vāvere, JS Lewis - Dalton transactions, 2007 - pubs.rsc.org
Copper (II)-diacetyl-bis (N4-methylthiosemicarbazone), Cu–ATSM, labeled with a positron
emitting isotope of copper (60Cu, 61Cu, 62Cu or 64Cu) has been shown, in vitro and in vivo …
emitting isotope of copper (60Cu, 61Cu, 62Cu or 64Cu) has been shown, in vitro and in vivo …
Copper-64-diacetyl-bis (N (4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia
PURPOSE: The behavior of copper-64-diacetyl-bis (N (4)-methylthiosemicarbazone)(64Cu-
ATSM) in hypoxic tumors was examined through a combination of in vivo dynamic positron …
ATSM) in hypoxic tumors was examined through a combination of in vivo dynamic positron …
Production and tumour uptake of [64 Cu] Pyruvaldehyde-bis (N 4-methylthiosemicarbazone) for PET and/or therapeutic purposes
AR Jalilian, P Rowshanfarzad… - Nuclear Medicine …, 2007 - journals.viamedica.pl
BACKGROUND: Copper-64 (T 1/2= 12.7ºh) is an important radionuclide used both in PET
imaging and therapy.[64 Cu]-pyruvaldehyde-bis (N 4-methylthiosemicarbazone)([64Cu] …
imaging and therapy.[64 Cu]-pyruvaldehyde-bis (N 4-methylthiosemicarbazone)([64Cu] …
Autoradiographic and small-animal PET comparisons between 18F-FMISO, 18F-FDG, 18F-FLT and the hypoxic selective 64Cu-ATSM in a rodent model of cancer
CS Dence, DE Ponde, MJ Welch, JS Lewis - Nuclear medicine and biology, 2008 - Elsevier
INTRODUCTION: Copper (II)-diacetyl-bis (N4-methylthiosemicarbazone), or Cu-ATSM, a
hypoxia imaging agent, has been shown to be predictive of response to traditional cancer …
hypoxia imaging agent, has been shown to be predictive of response to traditional cancer …
Cellular Uptake of the ATSM− Cu (II) Complex under Hypoxic Conditions
GR Walke, S Meron, Y Shenberger… - …, 2021 - Wiley Online Library
Abstract The Cu (II)‐diacetyl‐bis (N4‐methylthiosemicarbazone) complex (ATSM− Cu (II))
has been suggested as a promising positron emission tomography (PET) agent for hypoxia …
has been suggested as a promising positron emission tomography (PET) agent for hypoxia …
Intra-tumoral distribution of 64Cu-ATSM: a comparison study with FDG
A Obata, M Yoshimoto, S Kasamatsu, H Naiki… - Nuclear medicine and …, 2003 - Elsevier
64Cu-labeled diacetyl-bis (N4-methylthiosemicarbazone)(64Cu-ATSM) is a promising agent
for internal radiation therapy and imaging of hypoxic tissues. In the present study, the intra …
for internal radiation therapy and imaging of hypoxic tissues. In the present study, the intra …
Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET
Purpose Cu-diacetyl-bis (N 4-methylthiosemicarbazone (Cu-ATSM) is an effective marker for
the delineation of hypoxic tissue. Dosimetry calculations by the established Medical Internal …
the delineation of hypoxic tissue. Dosimetry calculations by the established Medical Internal …
Trace Metal Impurities Effects on the Formation of [64Cu]Cu-diacetyl-bis(N4-methylthiosemicarbazone) ([64Cu]Cu-ATSM)
M Shinada, H Suzuki, M Hanyu, C Igarashi… - Pharmaceuticals, 2023 - mdpi.com
[64Cu] Cu-diacetyl-bis (N 4-methylthiosemicarbazone)([64Cu] Cu-ATSM) is a radioactive
hypoxia-targeting therapeutic agent being investigated in clinical trials for malignant brain …
hypoxia-targeting therapeutic agent being investigated in clinical trials for malignant brain …